<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620498</url>
  </required_header>
  <id_info>
    <org_study_id>2209001086</org_study_id>
    <nct_id>NCT05620498</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.</brief_title>
  <official_title>An Open Phase II Clinical Study of Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in the Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Open Phase II Clinical Study of Tislelizumab Combined with Lenvatinib and GEMOX&#xD;
      Versus Tislelizumab Combined with GEMOX in the Treatment of Locally Advanced Intrahepatic&#xD;
      Cholangiocarcinoma and Gallbladder Cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>24 months</time_frame>
    <description>Improvement in quality of life as measured by the EORTC Quality of Life Questionnaire QLQ-C30 (V3.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>tislelizumab+lenvatinib+GMOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.&#xD;
Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd) for one year or until disease progression or toxicity became intolerable.&#xD;
Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd,) for one year or until disease progression or toxicity became intolerable.&#xD;
Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W, lenvatinib 8mg/kg, PO, qd for maintained treatment until disease progression or toxicity became intolerable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tislelizumab+GEMOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tislelizumab 200mg, Q3W, gemcitabine 1g/㎡, D1, D8, Q3W, oxaliplatin 100mg/㎡, D1, Q3W. Imaging evaluation was performed after 3 cycles.&#xD;
Patients who met surgical criteria will receive R0 resection and adjuvant therapy 4-8 weeks after surgery (tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.&#xD;
Inoperable patients continue to receive ≤4 cycles of treatment, imaging evaluation every two cycles. Patients will receive R0 resection if meet surgical criteria and adjuvant therapy 4-8 weeks after surgery (Tislelizumab 200mg, Q3W) for one year or until disease progression or toxicity became intolerable.&#xD;
Patients still unable to receive surgery, the experimental group will receive tislelizumab 200mg, Q3W for maintained treatment until disease progression or toxicity became intolerable.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tislelizumab+lenvatinib+GMOX</intervention_name>
    <description>tislelizumab 200mg, Q3W Lenvatinib 4mg Po QD Gemcitabine 1g/m2 Oxaliplatin 100mg/m, D1, q3W2</description>
    <arm_group_label>tislelizumab+lenvatinib+GMOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tislelizumab+GEMOX</intervention_name>
    <description>tislelizumab+GEMOX</description>
    <arm_group_label>tislelizumab+GEMOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1：Intrahepatic cholangiocarcinoma and gallbladder carcinoma confirmed by histology or&#xD;
        cytology.&#xD;
&#xD;
        Potential resectable criteria: The first stage R0 resection cannot be guaranteed for&#xD;
        patients with cholangiocarcinoma admitted to our hospital, and there are the following&#xD;
        imaging characteristics (satisfy one or more)&#xD;
&#xD;
          1. The hilar and retroperitoneal lymph nodes were considered for metastasis but could be&#xD;
             resected completely.&#xD;
&#xD;
          2. Intrahepatic cholangiocarcinoma has multiple foci, but foci are less than three and&#xD;
             limited to half of the liver.&#xD;
&#xD;
          3. Local progression of gallbladder carcinoma with colon or duodenal involvement.&#xD;
&#xD;
          4. Hilar cholangiocarcinoma or lower segment of cholangiocarcinoma involving portal vein&#xD;
             or hepatic artery requires combined vascular resection or reconstruction. 2. Patient&#xD;
             age: 20-79 years 3. At least one measurable lesion as defined in RECIST version 1.1 4.&#xD;
             ECOG score was 0-1 5.Life expectancy of at least 90 days 6.Aspartic aminotransferase&#xD;
             and alanine aminotransferase ≤150 IU/L in patients with bile drainage, and ≤100IU/L in&#xD;
             patients without bile drainage Total bilirubin ≤3.0 mg/dL in patients with bile&#xD;
             drainage and ≤2.0 mg/dL in patients without bile drainage.&#xD;
&#xD;
        7.Creatinine ≤1.5 mg/dL was used in the single treatment cohort and ≤1.2 mg/dL was used in&#xD;
        the combination treatment cohort; Creatinine clearance [measured or estimated using the&#xD;
        Cockcroft-Gault equation]≥45mL/min for the single treatment cohort and ≥50mL/min for the&#xD;
        combination treatment cohort 8.Neutrophil ≥1500 cells /µL, hemoglobin ≥9.0g/dL, platelet&#xD;
        ≥100000/µL 9.PD-L1 expression analysis and microsatellite unstable state analysis were&#xD;
        performed on tumor tissue samples.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with tislelizumab or anti-PD-1, PD-L1, PD-L2, CD137, CTLA-4&#xD;
             antibody, or any other therapy that regulates T cells&#xD;
&#xD;
          2. Received systemic corticosteroid or immunosuppressive therapy within 28 days before&#xD;
             inclusion&#xD;
&#xD;
          3. Concurrent autoimmune diseases or a history of chronic or recurrent autoimmune&#xD;
             diseases&#xD;
&#xD;
          4. A history of pleural adhesions or pericardium adhesions within 28 days prior to&#xD;
             inclusion&#xD;
&#xD;
          5. Test positive for HIV antibody, human T-cell leukemia virus type 1 antibody, hepatitis&#xD;
             C virus antibody, hepatitis B surface protein antigen, hepatitis B surface protein&#xD;
             antibody, hepatitis B core protein antibody or any detectable hepatitis B virus DNA&#xD;
&#xD;
          6. Multiple primary cancers (except completely resected basal cell carcinoma, stage I&#xD;
             squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, and superficial&#xD;
             bladder carcinoma, and any other cancer that has not recurred for at least 5 years)&#xD;
&#xD;
          7. Brain or meningeal metastases (unless asymptomatic and do not require treatment)&#xD;
&#xD;
          8. and uncontrolled or severe cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>huikai Li, Doctor</last_name>
    <phone>18622228639</phone>
    <email>tjchlhk@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dongming Liu, Doctor</last_name>
    <phone>18502261477</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huikai Li, MD</last_name>
      <phone>+862223340123</phone>
      <phone_ext>3091</phone_ext>
      <email>lihuikai@tjmuch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 4, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>November 16, 2022</last_update_submitted>
  <last_update_submitted_qc>November 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

